Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
200.88 +3.53 (+1.79%) 02/20/25 [NYSE]
198.42 x 100 201.53 x 300
Realtime by (Cboe BZX)
198.42 x 100 201.53 x 300
Realtime 200.50 -0.38 (-0.19%) 18:42 ET
Quote Overview for Thu, Feb 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
196.83
Day High
201.36
Open 198.00
Previous Close 197.35 197.35
Volume 5,066,900 5,066,900
Avg Vol 5,726,035 5,726,035
Stochastic %K 97.00% 97.00%
Weighted Alpha +16.78 +16.78
5-Day Change +7.88 (+4.08%) +7.88 (+4.08%)
52-Week Range 153.58 - 207.32 153.58 - 207.32
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 348,392,800
  • Shares Outstanding, K 1,765,355
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,137 M
  • EBITDA $ 17,835 M
  • 60-Month Beta 0.58
  • Price/Sales 6.15
  • Price/Cash Flow 12.41
  • Price/Book 57.12

Options Overview Details

View History
  • Implied Volatility 18.37% ( +0.68%)
  • Historical Volatility 24.93%
  • IV Percentile 17%
  • IV Rank 17.28%
  • IV High 30.36% on 10/29/24
  • IV Low 15.86% on 03/01/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 28,821
  • Volume Avg (30-Day) 21,995
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 334,812
  • Open Int (30-Day) 297,799

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.53
  • Number of Estimates 10
  • High Estimate 2.70
  • Low Estimate 2.48
  • Prior Year 2.31
  • Growth Rate Est. (year over year) +9.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
168.06 +19.53%
on 01/22/25
Period Open: 171.56
201.36 -0.24%
on 02/20/25
+29.32 (+17.09%)
since 01/17/25
3-Month
166.92 +20.35%
on 11/21/24
Period Open: 167.76
201.36 -0.24%
on 02/20/25
+33.12 (+19.74%)
since 11/20/24
52-Week
153.58 +30.80%
on 05/30/24
Period Open: 175.75
207.32 -3.11%
on 10/31/24
+25.13 (+14.30%)
since 02/20/24

Most Recent Stories

More News
2 Magnificent Dividend Growth Stocks to Load Up On Right Now

Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns since 1900, according to a report by the Hartford Funds. Companies that consistently...

SPGI : 535.43 (-1.34%)
ABBV : 200.88 (+1.79%)
4 Stocks and 1 Exchange-Traded Fund (ETF) I Can't Stop Buying

Five great investments for any portfolio.

GOOGL : 184.56 (-0.38%)
PLD : 120.90 (-0.60%)
SCHD : 28.32 (+0.50%)
ABBV : 200.88 (+1.79%)
AMZN : 222.88 (-1.65%)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 33.33 (+2.27%)
JNJ : 159.68 (+1.13%)
VRTX : 480.33 (+1.82%)
SNDX : 15.99 (+8.41%)
ABBV : 200.88 (+1.79%)
GERN : 2.63 (+3.54%)
RHHBY : 41.1500 (+1.16%)
PFE : 25.90 (+0.04%)
NTLA : 12.25 (-0.24%)
BMY : 55.79 (+1.47%)
BIIB : 137.08 (+0.29%)
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

BMRN : 68.73 (+4.76%)
GILD : 110.03 (+2.21%)
ABBV : 200.88 (+1.79%)
Is AbbVie Stock a Buy Now?

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in adjusted...

ABBV : 200.88 (+1.79%)
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs

This week, Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s RHHBY spinal muscular atrophy...

NVS : 107.31 (+0.37%)
ABBV : 200.88 (+1.79%)
RHHBY : 41.1500 (+1.16%)
PFE : 25.90 (+0.04%)
SNY : 54.13 (+0.99%)
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

VRTX : 480.33 (+1.82%)
ABBV : 200.88 (+1.79%)
BIIB : 137.08 (+0.29%)
Should Pfizer Stock Be in Your Portfolio Post a Robust Q4 Performance?

Pfizer’s PFE  fourth-quarter results were strong as it beat estimates for earnings as well as sales. Adjusted earnings per share of 63 cents were much higher than 10 cents in the year-ago quarter. Revenues...

NVO : 83.74 (+0.41%)
LLY : 873.12 (+0.70%)
ABBV : 200.88 (+1.79%)
PFE : 25.90 (+0.04%)
These Stocks Missed on Earnings, But Will Rebound Next Quarter

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

LLY : 873.12 (+0.70%)
LVS : 44.97 (+2.11%)
ABBV : 200.88 (+1.79%)
PFE : 25.90 (+0.04%)
Gilead Sciences (GILD) Q4 Earnings: What To Expect

Gilead Sciences (GILD) Q4 Earnings: What To Expect

GILD : 110.03 (+2.21%)
ABBV : 200.88 (+1.79%)
AMGN : 297.93 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 207.08
2nd Resistance Point 204.22
1st Resistance Point 202.55
Last Price 200.88
1st Support Level 198.02
2nd Support Level 195.16
3rd Support Level 193.49

See More

52-Week High 207.32
Last Price 200.88
Fibonacci 61.8% 186.79
Fibonacci 50% 180.45
Fibonacci 38.2% 174.11
52-Week Low 153.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements